{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T10:37:08Z","timestamp":1791715028016,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejpb.2012.09.018","type":"journal-article","created":{"date-parts":[[2012,10,17]],"date-time":"2012-10-17T14:19:28Z","timestamp":1350483568000},"page":"44-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis"],"prefix":"10.1016","volume":"83","author":[{"given":"Chris","family":"Rundfeldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Steckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Scherliess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Wyska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wla\u017a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2012.09.018_b0005","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1378\/chest.125.1_suppl.1S","article-title":"Cystic fibrosis adult care: consensus conference report","volume":"125","author":"Yankaskas","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2012.09.018_b0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4187\/aarc0446","article-title":"Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist","volume":"54","author":"O\u2019Malley","year":"2009","journal-title":"Respir. Care"},{"key":"10.1016\/j.ejpb.2012.09.018_b0015","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.1378\/chest.107.2_Supplement.61S","article-title":"Aerosol delivery of antibiotics to the lower airways of patients with cystic fibrosis","volume":"107","author":"Fiel","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2012.09.018_b0020","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.pupt.2009.06.001","article-title":"Tobramycin for inhalation in cystic fibrosis: beyond respiratory improvements","volume":"22","author":"Chuchalin","year":"2009","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2012.09.018_b0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14656566.2012.656090","article-title":"Tobramycin for the treatment of bacterial pneumonia in children","volume":"13","author":"Bothra","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejpb.2012.09.018_b0030","first-page":"21","article-title":"The clinical spectrum of aspergillosis \u2013 part 1: epidemiology, pathogenicity, infection in animals and immunology of Aspergillus","volume":"13","author":"Bardana","year":"1981","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.ejpb.2012.09.018_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3114\/sim.2007.59.01","article-title":"The current status of species recognition and identification in Aspergillus","volume":"59","author":"Geiser","year":"2007","journal-title":"Stud. Mycol."},{"key":"10.1016\/j.ejpb.2012.09.018_b0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis","volume":"26","author":"Denning","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2012.09.018_b0045","series-title":"Fungal Physiology","first-page":"375","article-title":"Spore dormancy and germination","author":"Griffin","year":"1994"},{"key":"10.1016\/j.ejpb.2012.09.018_b0050","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1378\/chest.121.6.1988","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"121","author":"Soubani","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2012.09.018_b0055","first-page":"863","article-title":"Aspergillosis and atopy in cystic fibrosis","volume":"120","author":"Nelson","year":"1979","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ejpb.2012.09.018_b0060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.08-2586","article-title":"Allergic bronchopulmonary aspergillosis","volume":"135","author":"Agarwal","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2012.09.018_b0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1081-1206(10)63157-2","article-title":"Antifungals in the treatment of allergic bronchopulmonary aspergillosis","volume":"82","author":"Leon","year":"1999","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.ejpb.2012.09.018_b0070","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/843763","article-title":"Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis","author":"Knutsen","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.ejpb.2012.09.018_b0075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1034\/j.1398-9995.2002.23583.x","article-title":"Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"57","author":"Skov","year":"2002","journal-title":"Allergy"},{"key":"10.1016\/j.ejpb.2012.09.018_b0080","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","article-title":"Characterization of the interaction of 2-hydroxypropyl-\u03b2-cyclodextrin with itraconazole at pH 2, 4, and 7","volume":"91","author":"Peeters","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2012.09.018_b0085","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1086\/313746","article-title":"Practice guidelines for the treatment of fungal infections. For the Mycoses study group. Infectious diseases society of America","volume":"30","author":"Sobel","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2012.09.018_b0090","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers","volume":"37","author":"Barone","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2012.09.018_b0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00007691-199710000-00007","article-title":"Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen","volume":"19","author":"Poirier","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejpb.2012.09.018_b0100","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.2042-7158.1992.tb05478.x","article-title":"The pharmacokinetics of oral itraconazole in AIDS patients","volume":"44","author":"Smith","year":"1992","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2012.09.018_b0105","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/03639040802144211","article-title":"Current therapies and technological advances in aqueous aerosol drug delivery","volume":"34","author":"Watts","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2012.09.018_b0110","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/17425247.2010.485608","article-title":"Ultrasonic nebulization platforms for pulmonary drug delivery","volume":"7","author":"Yeo","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2012.09.018_b0115","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/501915","article-title":"The epidemiology of invasive pulmonary aspergillosis at a large teaching hospital","volume":"22","author":"Pegues","year":"2001","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.ejpb.2012.09.018_b0120","first-page":"21","article-title":"Invasive pulmonary aspergillosis: a study of 39 cases at autopsy","volume":"50","author":"Vaideeswar","year":"2004","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.ejpb.2012.09.018_b0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2012.09.018_b0130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2008.05.003","article-title":"High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers","volume":"361","author":"Yang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2012.09.018_b0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejpb.2010.01.011","article-title":"Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats","volume":"75","author":"Yang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2012.09.018_b0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/08958378.2010.642021","article-title":"Nanoparticles: a review of particle toxicology following inhalation exposure","volume":"24","author":"Bakand","year":"2012","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.ejpb.2012.09.018_b0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/toxsci\/kfj084","article-title":"Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles","volume":"90","author":"Borm","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejpb.2012.09.018_b0150","series-title":"Physical Characterization of Pharmaceutical Solids","author":"Grant","year":"1995"},{"key":"10.1016\/j.ejpb.2012.09.018_b0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0378-5173(89)90069-0","article-title":"The effect of particle size distribution on dissolution rate and oral absorption","volume":"51","author":"Hintz","year":"1989","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2012.09.018_b0160","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1021\/la0523661","article-title":"Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening","volume":"22","author":"Lindfors","year":"2006","journal-title":"Langmuir"},{"key":"10.1016\/j.ejpb.2012.09.018_b0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2006.01.006","article-title":"Single dose and multiple dose studies of itraconazole nanoparticles","volume":"63","author":"Vaughn","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2012.09.018_b0170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2007.02.014","article-title":"Murine airway histology and intracellular uptake of inhaled amorphous itraconazole","volume":"338","author":"Vaughn","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2012.09.018_b0175","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/AAC.37.12.2762","article-title":"Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis","volume":"37","author":"Miyazaki","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2012.09.018_b0180","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1002\/jps.20878","article-title":"Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations","volume":"96","author":"Buchanan","year":"2007","journal-title":"J. Pharm. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.ejpb.2012.09.018_b0185","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dki220","article-title":"Making sense of itraconazole pharmacokinetics","volume":"56","author":"Prentice","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2012.09.018_b0190","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1128\/AAC.48.4.1197-1203.2004","article-title":"Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals","volume":"48","author":"Balajee","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2012.09.018_b0195","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.05077-11","article-title":"High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole","volume":"56","author":"Burgel","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2012.09.018_b0200","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1128\/AAC.39.6.1345","article-title":"Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis","volume":"39","author":"Allendoerfer","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2012.09.018_b0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/mmy.39.1.91.95","article-title":"Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species","volume":"39","author":"Ryder","year":"2001","journal-title":"Med. Mycol."},{"key":"10.1016\/j.ejpb.2012.09.018_b0210","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jac\/dki027","article-title":"Antitubercular inhaled therapy: opportunities, progress and challenges","volume":"55","author":"Pandey","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2012.09.018_b0215","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2012.09.018_b0220","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1378\/chest.119.1.169","article-title":"Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature","volume":"119","author":"Mehrad","year":"2001","journal-title":"Chest"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641112003165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641112003165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:30:16Z","timestamp":1760545816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641112003165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0939641112003165"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2012.09.018","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2012.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}